• Français (FR)
  • English (UK)
  • Home
  • Company
    • About us
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
      • Partnerships
  • Nox Science
    • NOX Enzymes
      • NADPH Oxidase
      • NOX Enzyme Family
      • NOX Expression
    • NOX and Disease
      • Oxidative Stress and Disease
      • Physiological Functions of NOX
      • Fibrotic diseases
      • Neurodegenerative diseases
      • Cardiovascular diseases
    • Publications
  • Pipeline
    • Setanaxib
    • Preclinical NOX1 program
    • Research programs
  • Investors
    • Stock information
    • Analyst coverage
    • Contribution project
      • Press release
      • Project presentation
      • Documentation
      • Shareholders general meeting
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Events and presentations
    • Regulated information
      • Financial information
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2015
        • 2014
      • Other regulated information
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
      • Governance
      • OCABSA warrants
    • Shareholder information
      • Shareholders’ meetings
        • 2021
        • 2020
        • 2019
          • AGM of June 13, 2019
          • AGE of January 2019
        • 2018
          • AGM of june 13, 2018
        • 2017
          • AGM of June 15, 2017
          • AGM of February 28, 2017
        • 2016
        • 2015
        • 2014
      • Agenda
  • News and Events
    • Press releases
    • Events and presentations
    • Media
      • Press clippings
      • Interviews
  • Contacts
  • Capital Increase
  • Investors /
  • Press releases /
  • 2021

Press release

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
2021-02-18 - 19:15

Genkyotex Announces 2020 Annual Financial Results And Provides Corporate Update

2021-01-27 - 10:00

Genkyotex provides Q4 business update and reports cash position

2021-01-22 - 07:00

Genkyotex announces update for near term clinical development plan for setanaxib

2021-01-18 - 08:00

Genkyotex announces positive Phase 1 results demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib

  • Stock information
  • Analyst coverage
  • Contribution project
    • Press release
    • Project presentation
    • Documentation
    • Shareholders general meeting
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
  • Events and presentations
  • Regulated information
    • Financial information
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2015
      • 2014
    • Other regulated information
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Governance
    • OCABSA warrants
  • Shareholder information
    • Shareholders’ meetings
      • 2021
      • 2020
      • 2019
        • AGM of June 13, 2019
        • AGE of January 2019
      • 2018
        • AGM of june 13, 2018
      • 2017
        • AGM of June 15, 2017
        • AGM of February 28, 2017
      • 2016
      • 2015
      • 2014
    • Agenda

Ask us your questions

Suscribe to Newsletter

  • Legal terms

Back to Top

© 2021 genkyotex.com